Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHKA | P35790 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.48 |
| ▸ | MAPT | P10636 | 7/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 5/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | NPC1 | O15118 | 3/20 | 0.48 |
| ▸ | TP53 | P04637 | 3/20 | 0.48 |
| ▸ | RAB9A | P51151 | 3/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | L3MBTL3 | Q96JM7 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL693166 | 0.97 | ALDH1A1 (0.52) | CHKAALDH1A1MAPTL3MBTL1KDM4E | |
| SCHEMBL146936 | 0.97 | ALDH1A1 (0.52) | CHKAALDH1A1MAPTL3MBTL1KDM4E | |
| SCHEMBL1900341 | 0.97 | ALDH1A1 (0.52) | CHKAALDH1A1MAPTL3MBTL1KDM4E | |
| SCHEMBL114702 | 0.95 | CHKA (0.46) | CHKAALDH1A1MAPTL3MBTL1KDM4E | |
| SCHEMBL5795262 | 0.89 | — | — | |
| SCHEMBL12478326 | 0.86 | ALDH1A1 (0.47) | CHKAALDH1A1MAPTL3MBTL1KDM4E | |
| SCHEMBL11747202 | 0.84 | ALDH1A1 (0.50) | CHKAALDH1A1MAPTL3MBTL1KDM4E | |
| SCHEMBL2323102 | 0.83 | LMNA (0.50) | CHKAALDH1A1MAPTKDM4EALOX15 | |
| SCHEMBL215829 | 0.81 | NCF1 (0.58) | CHKAALDH1A1MAPTKDM4EKMT2A | |
| SCHEMBL215813 | 0.81 | ADRB1 (0.53) | ALDH1A1KDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1718 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230339904-A1 | ISOINDOLINONES, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. | 2023-10-26 | — | — | US | claimed |
| US-20220389009-A1 | SUBSTITUTED 1,6-NAPHTHYRIDINE INHIBITORS OF CDK5 | GFB (ABC), LLC | 2022-12-08 | — | — | US | claimed |
| CN-114761000-A | Substituted 1, 6-naphthyridine inhibitors of CDK5 | 金翅雀生物公司 | 2022-07-15 | — | — | CN | claimed |
| EP-3997083-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND/OR TRYPTOPHAN 2,3-DIOXYGENASE | Idorsia Pharmaceuticals Ltd (CH) | 2022-05-18 | — | — | EP | claimed |
| CN-114127066-A | Inhibitors of indoleamine 2, 3-dioxygenase and/or tryptophan 2, 3-dioxygenase | 爱杜西亚药品有限公司 | 2022-03-01 | — | — | CN | claimed |
| WO-2022011274-A1 | SUBSTITUTED 1,6-NAPHTHYRIDINE INHIBITORS OF CDK5 | GOLDFINCH BIO, INC. (US) | 2022-01-13 | — | — | WO | claimed |
| CN-110128257-B | 1-phenyl-4-pentene-1-one derivative and synthesis method and application thereof | 华东师范大学 | 2021-10-15 | — | — | CN | claimed |
| WO-2021078132-A1 | INHIBITORS OF MTOR-MEDIATED INDUCTION OF AUTOPHAGY | SIRONAX LTD (GB) | 2021-04-29 | — | — | WO | claimed |
| WO-2021067569-A1 | SUBSTITUTED 1, 6-NAPHTHYRIDINE INHIBITORS OF CDK5 | GOLDFINCH BIO, INC. (US) | 2021-04-08 | — | — | WO | claimed |
| WO-2021005222-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND/OR TRYPTOPHAN 2,3-DIOXYGENASE | IDORSIA PHARMACEUTICALS LTD (CH) | 2021-01-14 | — | — | WO | claimed |
| US-5733931-A | ANTICHOLESTEROL AGENTS | NISSIN FOOD PRODUCTS CO., LTD. (JP) | 1998-03-31 | — | — | US | claimed |
| EP-0718281-A1 | CYCLOHEXANEDIUREA DERIVATIVE AND PROCESS FOR PRODUCING THE SAME | NISSIN FOOD PRODUCTS CO., LTD. (JP) | 1996-06-26 | — | — | EP | claimed |
| US-5134150-A | Administering diaryl-substituted imidazothiazoles; antiarthritic agents | SMITHKLINE BEECHAM CORPORATION (US) | 1992-07-28 | — | — | US | claimed |
| US-4716168-A | STIMULANTS OF IMMUNE RESPONSE | NORWICH EATON PHARMACEUTICALS, INC. (US) | 1987-12-29 | — | — | US | claimed |
| EP-0231622-A2 | Inhibition of the 5-lipoxygenase pathway | SMITHKLINE BEECHAM CORPORATION (US) | 1987-08-12 | — | — | EP | claimed |
| EP-0187705-A2 | Imidazo(4,5-f)quinolines useful as immunomodulating agents | Norwich Eaton Pharmaceuticals, Inc. (US) | 1986-07-16 | — | — | EP | claimed |
| EP-0051990-B1 | BIOLOGICALLY ACTIVE HETEROBICYCLIC HYDROXIMIDATES AND THIOLHYDROXIMIDATES AND CARBAMATE ESTER DERIVATIVES THEREOF | SDS BIOTECH CORPORATION (US) | 1986-01-02 | — | — | EP | claimed |
| US-4420548-A | Electrophotographic member with hydrazone or ketazine compounds | CANON KABUSHIKI KAISHA (JP) | 1983-12-13 | — | — | US | claimed |
| US-4119776-A | Vinyl phthalide color formers | NCR CORPORATION (US) | 1978-10-10 | — | — | US | claimed |
| US-4107428-A | PHTHALIDE COMPOUNDS | NCR CORPORATION (US) | 1978-08-15 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230339904-A1 | ISOINDOLINONES, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | CSNK1A1, CSNK1D, CSNK1G1 | CHKA 286/4885ALDH1A1 1318/4885MAPT 922/4885 |
| US-20220389009-A1 | SUBSTITUTED 1,6-NAPHTHYRIDINE INHIBITORS OF CDK5 | CDK5, CDK5R1, PKD1 | CHKA 494/4885ALDH1A1 2375/4885MAPT 621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.